Olszewska Barbara, Adamski Zygmunt, Czarnecka-Operacz Magdalena
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
Postepy Dermatol Alergol. 2018 Jun;35(3):231-237. doi: 10.5114/ada.2018.76086. Epub 2018 Jun 18.
Psoriasis is a chronic autoimmune disease that affects approximately 2-3% of the world's population. Although the cutaneous manifestations of the disease are the most prevalent, psoriasis is also associated with a systemic inflammation and various co-morbidities linked with autoinflammatory processes. One of those processes is psoriatic arthritis, an inflammatory, seronegative spondyloarthropathy that develops in 13.8-30% of psoriatic patients at some point of their lives. Over the past 15 years the therapeutic options for severe and generalized psoriasis have broadened immensely with the introduction of biological agents to everyday practice. We present a quick overview of current biological therapies in the treatment of psoriasis and prospects for forthcoming advancements in biological treatment.
银屑病是一种慢性自身免疫性疾病，影响着全球约2%-3%的人口。尽管该疾病的皮肤表现最为常见，但银屑病还与全身炎症以及与自身炎症过程相关的各种合并症有关。其中一个过程就是银屑病关节炎，这是一种炎症性、血清阴性脊柱关节病，在13.8%-30%的银屑病患者一生中的某个阶段会出现。在过去15年里，随着生物制剂引入日常临床实践，重度和泛发性银屑病的治疗选择大幅增加。我们简要概述了目前治疗银屑病的生物疗法以及生物治疗未来进展的前景。
